| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Estrogen receptor (ER), particularly ERβ. Medicarpin acts as an estrogen receptor agonist. It can stimulate osteoblast differentiation likely via ERβ. The compound also modulates P-glycoprotein-mediated efflux of chemotherapeutic agents. It induces apoptosis and counteracts multidrug resistance in leukemia cells.
|
|---|---|
| ln Vitro |
Medicarpin (90 µM; for 48 h) triggers apoptosis in sensitive as well as multidrug resistant P388/DOX cells that express P-glycoprotein do not exhibit resistance to medicarpin (IC50≈90 µM for P388 and P388/DOX cells)[1].
Medicarpin induces apoptosis and counteracts multidrug resistance in leukemia P388 cells by modulating P-gp-mediated efflux of agents. It acts as an estrogen receptor agonist and can stimulate osteoblast differentiation likely via ERβ. The compound promotes achievement of peak bone mass. It is devoid of uterine estrogenicity. |
| ln Vivo |
Medicarpin has excellent oral bioavailability and can potentially be used as an osteogenic agent. It promotes achievement of peak bone mass and is devoid of uterine estrogenicity. The compound has been studied for its potential in treating osteoporosis and other bone-related conditions.
|
| Enzyme Assay |
Medicarpin is evaluated in cell-free receptor binding assays using estrogen receptor proteins. Radioligand binding displacement assays are performed to determine the affinity of Medicarpin for ERα and ERβ. Competition binding experiments are conducted with increasing concentrations of Medicarpin and a fixed concentration of a labeled reference ligand. The compound's ability to modulate P-glycoprotein activity can also be assessed in cell-free systems.
|
| Cell Assay |
Medicarpin is assessed in cell-based assays using leukemia P388 cells. Cells are treated with Medicarpin, and apoptosis is measured using flow cytometry or caspase activity assays. The compound's ability to modulate P-glycoprotein-mediated efflux is assessed by measuring intracellular accumulation of chemotherapeutic agents. Osteoblast differentiation is assessed using appropriate cell models.
|
| Animal Protocol |
Medicarpin is administered orally in animal models to evaluate its effects on bone mass and osteoporosis. It promotes achievement of peak bone mass and is devoid of uterine estrogenicity. Efficacy is assessed by measuring bone density and osteoblast differentiation. The compound has excellent oral bioavailability.
|
| ADME/Pharmacokinetics |
Medicarpin has excellent oral bioavailability. It has a molecular weight of 270.28 and a molecular formula of C16H14O4. The compound has a CAS number of 32383-76-9 and a UNII code of 6TX086I6IG. It is a flavonoid phytoalexin derived from Medicago sativa.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Medicarpin. The compound is for research use only and is not intended for human therapeutic use. It is devoid of uterine estrogenicity, suggesting a favorable safety profile compared to other estrogen receptor agonists. However, specific toxicity studies have not been well-characterized.
|
| References | |
| Additional Infomation |
(-)-Alfalfacin is the (-)-enantiomer of alfalfacin, a plant metabolite. It is the enantiomer of (+)-alfacin. Alfacin has been reported in Caragana frutex, Lathyrus grandiflorus, and other organisms with relevant data. See also: Glycyrrhiza uralensis root (part); Medicago sativa whole plant (part).
Medicarpin is a flavonoid phytoalexin derived from Medicago sativa that functions as an apoptosis inducer and estrogen receptor agonist. It has a molecular weight of 270.28 and a molecular formula of C16H14O4. The compound has a CAS number of 32383-76-9 and a UNII code of 6TX086I6IG. It induces apoptosis and counteracts multidrug resistance in leukemia cells. It promotes achievement of peak bone mass and is devoid of uterine estrogenicity. The compound is for research use only and has not been approved for clinical use. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.28
|
| Exact Mass |
270.089
|
| Elemental Analysis |
C, 71.10; H, 5.22; O, 23.68
|
| CAS # |
32383-76-9
|
| Related CAS # |
(+)-Medicarpin;33983-39-0
|
| PubChem CID |
336327
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
418.8±45.0 °C at 760 mmHg
|
| Melting Point |
127.5-128.5°
|
| Flash Point |
207.1±28.7 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.630
|
| LogP |
2.72
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=CC2=C(C=C1)[C@@H]3COC4=C(C=CC(=C4)O)[C@@H]3O2
|
| InChi Key |
NSRJSISNDPOJOP-CZUORRHYSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m0/s1
|
| Chemical Name |
(6aR,11aR)-9-methoxy-6a,11a-dihydro-6H-[1]benzofuro[3,2-c]chromen-3-ol
|
| Synonyms |
Medicarpin; Medicarpin, (-)-; Demethylhomopterocarpin; NSC-350085; NSC350085; NSC 350085
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~185.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA